P. Kung

发表

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

J. Christensen, B. Mroczkowski, L. Funk, 2011, Journal of medicinal chemistry.

Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.

L. Funk, P. Kung, J. Meng, 2008, Bioorganic & medicinal chemistry letters.

Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.

K. Gajiwala, M. Hickey, P. Kung, 2011, Bioorganic & medicinal chemistry letters.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Shinji Yamazaki, Gordon Alton, Pei-Pei Kung, 2007, Cancer research.

Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents.

P. D. Cook, D. Ecker, J. Wyatt, 1999, Journal of medicinal chemistry.

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model

Paolo Vicini, Shinji Yamazaki, Pei-Pei Kung, 2011, Journal of Pharmacology and Experimental Therapeutics.

Abstract 2612: Effective targeting triple negative breast cancer cells by a novel oral heat shock protein 90 inhibitor PF-4942847

P. Kung, S. Yamazaki, M. Gehring, 2011 .

Rapid, Microwave-Assisted Synthesis of N1-Substituted 3-Amino-1,2,4-triazoles.

P. Kung, J. Meng, 2009 .

Rapid, microwave-assisted synthesis of N1-substituted 3-amino-1,2,4-triazoles

P. Kung, J. Meng, 2009 .

Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.

K. Gajiwala, M. Hickey, P. Kung, 2010, Journal of medicinal chemistry.

Crizotinib (Xalkori): The First‐in‐Class ALK/ROS Inhibitor for Non‐small Cell Lung Cancer

P. Kung, P. Richardson, Ricky Jones, 2015 .

Solution-phase simultaneous addition of functionalities (SPSAF) and chemical transformation to prepare N,N'-disubstituted piperazine libraries.

P. D. Cook, P. Kung, 1998, Biotechnology and bioengineering.

Monitoring solution-phase combinatorial library synthesis by capillary electrophoresis.

P. D. Cook, P. Kung, D. Brooks, 1998, Biotechnology and bioengineering.

6-O-(Pentafluorophenyl)-2'-deoxyguanosine: a versatile synthon for nucleoside and oligonucleotide synthesis

Roger A. Jones, B. Gaffney, P. Kung, 1992 .

One-Flask Syntheses of 6-Thioguanosine and 2′-Deoxy-6-Thioguanosine

Roger A. Jones, P. Kung, 1991 .

Nitrogen-15-labeled deoxynucleosides. 2. Synthesis of 7-15N-labeled deoxyadenosine, deoxyguanosine, and related deoxynucleosides

Roger A. Jones, B. Gaffney, P. Kung, 1990 .

Nitrogen-15-labeled oligodeoxynucleotides. 8. Use of 15N NMR to probe Hoogsteen hydrogen bonding at guanine and adenine N7 atoms of a DNA triplex

Roger A. Jones, B. Gaffney, P. Kung, 1995 .

H-phosphonate DNA synthesis without amino protection

Roger A. Jones, P. Kung, 1992 .

Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates.

L. Kuhn, P. W. Rose, P. Kung, 2005, Bioorganic & Medicinal Chemistry Letters.

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

K. Gajiwala, P. Kung, A. Brooun, 2016, Nature Communications.

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquin

K. Gajiwala, N. Sach, P. Kung, 2017, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3 , 4-Dihydroisoquinoline-1 ( 2 H ) ‐ ones as a Novel Class of Enhancer of Zeste Homolog 2 ( EZH 2 ) Inhibitors

P. Kung, S. Yamazaki, M. Edwards, 2016 .

SAH derived potent and selective EZH2 inhibitors.

K. Gajiwala, P. Kung, K. Maegley, 2015, Bioorganic & medicinal chemistry letters.

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

P. Kung, S. Yamazaki, M. Yin, 2011, Clinical Cancer Research.

Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer

Zhou Zhu, P. Kung, A. Blasina, 2014, Molecular Cancer Therapeutics.

Companion Diagnostics and Cancer Biomarkers Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer

Zhou Zhu, P. Kung, A. Blasina, 2014 .

Harnessing Ionic Selectivity In Acetyltransferase Chemoproteomic Probes

M. Washburn, L. Florens, P. Kung, 2020 .

Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.

W. K. Sonnenburg, P. Kung, Sergei L Timofeevski, 2020, ACS medicinal chemistry letters.

Solution-Phase Synthesis of Novel Linear Oxyamine Combinatorial Libraries with Antibacterial Activity

P. D. Cook, P. Kung, A. Kawasaki, 1998 .

Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of Medicinal Chemistry.

Solution-Phase Synthesis of Novel Linear Oxyamine Combinatorial Libraries with Antibacterial Activity.

P. D. Cook, P. Kung, A. Kawasaki, 1998 .

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.

P. Kung, S. Yamazaki, M. Gehring, 2011, Cancer letters.

Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyri

K. Gajiwala, M. Hickey, P. Kung, 2011, Journal of medicinal chemistry.

Methyl 3-[3-(ethoxycarbonyl)thioureido]-1H-pyrazole-5-carboxylate

Arnold L. Rheingold, Alex Yanovsky, Buwen Huang, 2009, Acta crystallographica. Section E, Structure reports online.

Synthesis and evaluation of novel bacterial rRNA-binding benzimidazoles by mass spectrometry.

R. Griffey, P. Kung, V. Mohan, 2004, Bioorganic & medicinal chemistry letters.

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.

Chin Wee Tan, Dharmesh D. Bhuva, Eric C Greenwald, 2023, Cell chemical biology.

EZH2 as a therapeutic target in solid tumors

A. Barsotti, P. Kung, R. A. Rollins, 2015 .

Harnessing Ionic Selectivity In Acetyltransferase Chemoproteomic Probes

M. Washburn, L. Florens, P. Kung, 2020, bioRxiv.

Identification of small-molecule protein–protein interaction inhibitors for NKG2D

Jennifer D. Venable, J. Edwards, A. Thompson, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.

W. K. Sonnenburg, P. Kung, M. Gehring, 2020, ACS medicinal chemistry letters.